NovImmune focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The lead candidate, emapalumab, is an orphan drug for the treatment of primary Haemophagocytic lymphohistiocytosis (HLH), an orphan disease for which no drugs have been approved. Assets were acquired by Sobi for CHF 515 million in 2019.